Search
Search Results
##search.searchResults.foundPlural##
-
JUSTIFICATION OF UNIVERSAL IRON SUPPLEMENTATION FOR INFANTS 6-12 MONTHS IN REGIONS WITH A HIGH PREVALENCE OF THALASSEMIA Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia
1992PDF: 585Suppl. Files: 272HTML: 153 -
AGING WITH THALASSEMIA AND SICKLE CELL DISEASE: A GERONTOLOGICAL MODEL OF ACCELERATED MULTIMORBIDITY AND FUNCTION-CENTERED CARE BEYOND MIDLIFE Thalassemia and Sickle Cell Diseases: Effect of Aging
100PDF: 55Suppl. Files: 22HTML: 5 -
-
QUALITY OF LIFE IN PATIENTS WITH THALASSEMIA MAJOR AND INTERMEDIA IN KERMAN-IRAN (I.R.)
1613PDF: 734HTML: 2328Cover Letter: 166 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
2795PDF: 1550HTML: 221 -
CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.
4160PDF: 1493HTML: 433 -
-
A SEROPREVALENCE OF HBV, HCV AND HIV-1 AND CORRELATION WITH MOLECULAR MARKERS AMONG MULTI-TRANSFUSED THALASSEMIA PATIENTS IN WESTERN INDIA Incidence of serology & molecular of HIV, HBV and HCV in thalassemia patients
1284PDF: 744HTML: 475 -
END-OF-LIFE CARE IN SICKLE CELL DISEASE AND TRASFUSION DEPENDEND-β-THALASSEMIA: CLINICAL, PSYCHOLOGICAL, AND ETHICAL CONSIDERATION Challenges in Supportive Care, Equity, and Compassion at End of Life
921PDF: 587Html: 149 -
-
A MULTICENTER ICET-A SURVEY ON ADHERENCE TO ANNUAL ORAL GLUCOSE TOLERANCE TEST (OGTT) SCREENING IN TRANSFUSION-DEPENDENT THALASSEMIA (TDT) PATIENTS - THE EXPERT CLINICIANS’ OPINION ON FACTORS INFLUENCING THE ADHERENCE AND ON ALTERNATIVE STRATEGIES FOR ADHERENCE OPTIMIZATION Survey on adherence to annual OGTT in thalassemia
2823PDF: 1294HTML: 150 -
High Prevalence of Antiphospholipid Antibodies in Children with Non-Transfusion Dependent Thalassemia and Possible Correlations with Microparticles Antiphospholipid Antibodies and Thalassemia in children
835PDF: 575HTML: 267 -
THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone
2297PDF: 1554HTML: 591 -
MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY
3327PDF: 1268HTML: 1853Fig.1: 184Fig. 2: 190 -
THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA
2523PDF: 806HTML: 14930Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 277 -
GROWTH AND ENDOCRINE FUNCTION IN TUNISIAN THALASSEMIA MAJOR PATIENTS
2683PDF: 981HTML: 402TABLE: 172FIGURES: 217 -
Concordance Rate of Fasting Plasma Glucose (PG) and 2-hour PG post Oral Glucose Tolerance Test (OGTT) in Patients with new diagnosis of Thalassemia-Related Diabetes Mellitus (Th-RDM):Implications for Clinical Practice OGTT concordance rate in thalassemia major
553PDF: 409Html: 97 -
GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload
3835PDF: 1074HTML: 414 -
-
CAN WE PREDICT INCIPIENT DIABETES MELLITUS IN PATIENTS WITH TRANSFUSION DEPENDENT β-THALASSEMIA (β-TDT) REFERRED WITH A HISTORY OF PREDIABETES? Risk factors for incipient diabetes in thalassemia
1008PDF: 1314HTML: 93 -
PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?
2894PDF: 946HTML: 2053Cover letter: 164 -
EFFICACY AND SAFETY OF SINOPHARM VACCINE FOR SARS-COV-2 AND BREAKTHROUGH INFECTIONS IN IRANIAN PATIENTS WITH HEMOGLOBINOPATHIES: A PRELIMINARY REPORT Sinopharm Vaccination in Iranian Patients with Hemoglobinopathies
1470PDF: 696HTML: 217







